Medical management of melanoma

Brown, Charles K.; Kirkwood, John M.

doi:10.1016/s0039-6109(02)00187-1

Cited by 28 publications

(15 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melittin, which consists of 26 amino acid residues, is a cationic, hemolytic peptide isolated from honeybee venom. Previous studies have demonstrated that melittin has antibacterial, anti-arthritic and anti-inflammatory activities in various cell lines (6). Additionally, melittin has been shown to be a promising anticancer drug.…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy and biochemotherapy have also been used in the treatment of advanced melanoma. However, these treatments lack sufficient efficacy, and their toxicity and significant side effects greatly restrict their clinical application (6). Therefore, it is necessary to find an efficient and low-toxic anticancer drug for patients with thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TT‑1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl‑2 and Bax

Wan

Zhang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Melittin is a 26 amino acid residue antimicrobial peptide with known antitumor activity. In the present study, a novel peptide TT-1, derived from melittin and contained only 11 amino acids, was designed, and its antitumor effect was investigated. The present study is aimed to elucidate the effects and relative mechanisms of TT-1 on a human thyroid cancer cell line (TT) in vitro and in vivo. Cell viability assays, Annexin V/propidium iodide assays, western blotting and quantitative reverse transcription polymerase chain reaction were performed. Furthermore, a tumor-xenograft model was established to investigate the apoptotic mechanisms of TT-1 on TT cells. The results obtained indicated that TT-1 was able to suppress the proliferation of TT cells and exhibited low cytotoxicity to normal thyroid cells in vitro. The apoptotic rates of TT cells were also increased following TT-1 treatment. Additionally, TT-1 stimulated caspase-3, caspase-9 and Bax, and inhibited B-cell lymphoma 2 mRNA and protein expression. Finally, it was also demonstrated that TT-1 is able to markedly suppress tumor growth in a TT-bearing nude mouse model. In summary, TT-1 may inhibit the proliferation of TT cells by inducing apoptosis in vitro and in vivo, indicating that TT-1 may be a potential candidate for the treatment of thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

TT‑1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl‑2 and Bax

Wan

Zhang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…In this stage of advanced disease, chemotherapy never has shown an overall survival benefit, although it induces occasional transient disease regression. Immunotherapy demonstrates more notable effects, with durable responses achieved by high-dose interleukin 2 and interferon leading to the approval of the former for therapy of metastatic disease and the evaluation of the latter as an adjuvant therapy [78]. The apparent inability of any agent tested to improve overall survival in melanoma emphasizes the need for alternative therapies.…”

Section: Detection Of Recurrencementioning

confidence: 99%

Novel Imaging Techniques in Melanoma

Essner¹,

Belhocine²,

Scott³

et al. 2006

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

“…With the frequency of cases rising rapidly, melanoma has become one of the most fatal cancers in the past few years worldwide, especially in the white population (1,2). Surgical resection, chemotherapy, and immunotherapy are the conventional therapeutic strategies for patients with malignant melanoma.…”

Section: Introductionmentioning

confidence: 99%

Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle

Yao

Huo

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Interleukin-2 (IL-2) has been shown to possess antitumor activity in numerous preclinical and clinical studies. However, the short half-life of recombinant IL-2 protein in serum requires repeated high-dose injections, resulting in severe side effects. Although adenovirus-mediated IL-2 gene therapy has shown antitumor efficacy, the host antibody response to adenoviral particles and potential biosafety concerns still obstruct its clinical applications. Here we report a novel nanopolymer for IL-2 delivery, consisting of low molecular weight polyethylenimine (600Da) linked by b-cyclodextrin and conjugated with folate (named H1). H1 was mixed with IL-2 plasmid to form H1/pIL-2 polyplexes of around 100 nm in diameter. Peritumoral injection of these polyplexes suppressed the tumor growth and prolonged the survival of C57/BL6 mice bearing B16-F1 melanoma grafts. Importantly, the antitumor effects of H1/pIL-2 (50 mg DNA) were similar to those of recombinant adenoviruses expressing IL-2 (rAdv-IL-2; 2 Â 10 8 pfu). Furthermore, we showed that H1/pIL-2 stimulated the activation and proliferation of CD8þ, CD4þ T cell, and natural killer cells in peripheral blood and increased the infiltration of CD8þ, CD4þ Tcells, and natural killer cells into the tumor environment. In conclusion, these results show that H1/pIL-2 is an effective and safe melanoma therapeutic with an efficacy comparable to that of rAdv-IL-2. This treatment represents an alternative gene therapy strategy for melanoma. Mol Cancer Ther; 10(6); 1082-92. Ó2011 AACR.

show abstract

Medical management of melanoma

Cited by 28 publications

References 133 publications

TT‑1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl‑2 and Bax

TT‑1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl‑2 and Bax

Novel Imaging Techniques in Melanoma

Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle

Contact Info

Product

Resources

About